Stock comparison
Eli Lilly
Viatris
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
LLY
Eli Lilly
Market cap
$1T
Sector
Healthcare
VTRS
Viatris
Market cap
$19.39B
Sector
Healthcare
Overall winner
Eli Lilly LLY
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | LLY | VTRS | Winner |
|---|---|---|---|
| Warren Buffett | 72B | 31F | LLY |
| Benjamin Graham | 86A | 27F | LLY |
| Philip Fisher | 86A | 18F | LLY |
| Peter Lynch | 74B | 7F | LLY |
| Joel Greenblatt | 78C | 0F | LLY |
| Charlie Munger | 85A | 26F | LLY |
| Terry Smith | 77C | 17F | LLY |
Side-by-side metrics
| Metric | LLY | VTRS |
|---|---|---|
| Market cap | $1T | $19.39B |
| P/E (TTM) | 36.6x | - |
| EV/EBIT | 34.1x | - |
| ROIC (TTM) | 32.06% | 0.16% |
| Gross margin | 83.51% | 34.4% |
| Net margin | 34.98% | -2.04% |
| Revenue CAGR 5y | 23.17% | -5.44% |
| EPS CAGR 5y | 40.81% | -69.69% |
| Debt / Equity | 1.4x | 1.0x |
| Dividend yield | 0.62% | 2.8% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
LLY leads on
- EPS CAGR 5y40.81%vs -69.69%+159%
- Revenue CAGR 5y23.17%vs -5.44%+123%
- Net margin34.98%vs -2.04%+106%
- ROIC (TTM)32.06%vs 0.16%+100%
VTRS leads on
- P/E (TTM)-vs 36.6x+155%
- EV/EBIT-vs 34.1x+136%
- Dividend yield2.8%vs 0.62%+78%
- Debt / Equity1.0xvs 1.4x+30%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.